<DOC>
	<DOCNO>NCT01560754</DOCNO>
	<brief_summary>The primary objective study demonstrate transdermal nicotine treatment retard disease progression measure change total Unified Parkinson 's Disease Rating Scale ( UPDRS ) ( part I , II , III ) score baseline 52 week study treatment plus two month wash ( 60 week ) .</brief_summary>
	<brief_title>Disease-modifying Potential Transdermal NICotine Early Parkinson 's Disease</brief_title>
	<detailed_description>In order prove disease-modifying potential transdermal nicotine treatment , explanatory design 2 month wash-out phase endpoint assessment perform . The primary objective demonstrate superiority measure difference nicotine arm placebo arm change total UPDRS score ( part I-III ) baseline end month 14 ( 12 month treatment 2 month wash-out , see 3.1 ) . The total UPDRS score determine independent rater , involve study-related procedure ( e.g . report adverse event ) . Change total UPDRS score widely apply measure similar clinical trial assess long-term beneficial effect drug . The investigator also determine whether slope curve total UPDRS score active- placebo-treated subject show tendency converge time . For purpose UPDRS determine three time placebo/nicotine withdrawal end study Visit 7,8 , 9 ( i.e . four time include Visit 6 ) . Approximately 250 subject screen 25-30 center Germany USA . The recruitment period 18 month . In screen phase , subject evaluate eligibility enrolment treatment phase . The investigator expect screen 250 subject result 160 eligible subject randomly assign 1:1 treatment either transdermal nicotine transdermal placebo patch . The treatment phase consist titration period ( 16 week , find high dosage tolerate subject target 28 mg ) maintenance period ( week 17 week 52 high tolerate dosage nicotine ) . The treatment phase follow 8 week wash-out phase ( 3 week titration 5 week run ) . Dose adjustment permit adverse event document thoroughly .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Written inform consent 2 . Capability willingness comply study relate procedure 3 . Age &gt; /= 30 4 . Usage effective contraception ( see ) fertile premenopausal female participant ( inclusion end wash ) Acceptable form effective contraception include establish use oral , injected implant hormonal method contraception , placement intrauterine device ( IUD ) intrauterine system ( IUS ) , barrier method contraception ( condom occlusive cap /diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository male / female sterilization / true abstinence . 5 . Diagnosis PD accord UK Brain Bank Diagnostic Criteria 6 . Early PD subject within 18 month diagnosis 7 . Hoehn Yahr stage ≤ 2 8 . Patients receive need dopamine agonist levodopa therapy presently next year 9 . Stable treatment ( &gt; 2 month ) MAOB inhibitor ( selegiline 10 mg/d rasagiline 1 mg/d ) allowable 1 . Clinical sign indicate Parkinson syndrome idiopathic PD e.g . : Supranuclear gaze palsy Signs frontal dementia History repeat stroke stepwise progression Parkinsonian feature History repeat head injury history definite encephalitis Cerebellar sign Early severe autonomic involvement Babinski 's sign 2 . History exposure current treatment neuroleptic drug anticraving substance 3 . History nicotine use within five year baseline visit 4 . Previous history allergic response nicotine application patch excipients ( see protocol sec . 10.2 ) 5 . Previous history allergic response transdermal patch 6 . Preexisting dermatological disorder could disturb transdermal patch application opinion investigator ( e.g . generalize / systemic local neurodermatitis , psoriasis , chronic dermatitis , urticaria , etc . ) 7 . Previous treatment antiparkinsonian drug ( e.g . levodopa , dopamine agonist , etc . ) MAOB inhibitor 8 . History unstable serious cardiovascular disease Unstable worsen angina pectoris , History recent myocardial infarction cardiac failure ( NYHA II IV ) , myocardial insufficiency History inclusion serious cardiac arrhythmia , History recent stroke occlusive peripheral vascular disease , vasospasm 9 . History structural brain disease , cerebrovascular disease 10 . History severe uncontrolled arterial hypertension 11 . History severe pulmonary disease ( asthma , COPD ) 12 . History autoimmune disease 13 . History Hyperthyroidism 14 . History Pheochromocytoma 15 . History seizure / epilepsy 16 . History amyosthenia / myasthenia gravis , pseudomyasthenic syndrome 17 . Dementia define Mini Mental State Examination ( MMSE ) score ≤ 24 18 . Moderate depression ( BDIII score &gt; 24 ) 19 . Suicide suicide ideation 20 . History presence specific psychiatric disorder , acute psychosis , hallucination , pathologic gambling , alcohol substance abuse 21 . Patients treatment dihydropyridines ( e.g . nifedipine , nicardipine , amlodipine ) 22 . History uncontrolled diabetes 23 . History recent gastroduodenal ulcer ( &lt; 3 month ) presence severe ( acute chronic ) gastritis 24 . History known hepatobiliary renal insufficiency 25 . Pregnancy lactation period 26 . Simultaneous participation previous participation within 60 day screen another clinical drug medical device study . Other Trials affect NICPD Study ( NIT , health economics evaluation , questionnaire , genetic study ) could allow , approve documented steer committee</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Multi-center</keyword>
	<keyword>Disease-modifying potential</keyword>
	<keyword>transdermal nicotine</keyword>
</DOC>